(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 483.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Oculis Holding Ag's revenue in 2025 is $355,555.On average, 9 Wall Street analysts forecast OCS's revenue for 2025 to be $51,743,930, with the lowest OCS revenue forecast at $43,805,852, and the highest OCS revenue forecast at $63,864,909. On average, 9 Wall Street analysts forecast OCS's revenue for 2026 to be $504,046,670, with the lowest OCS revenue forecast at $43,805,852, and the highest OCS revenue forecast at $2,405,410,614.
In 2027, OCS is forecast to generate $4,712,369,810 in revenue, with the lowest revenue forecast at $153,320,481 and the highest revenue forecast at $12,848,412,789.